Ophthalmic Anti-Inflammatories
Therapeutic Class Review (TCR)

January 12, 2017

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management.

All requests for permission should be mailed to:

Magellan Rx Management
Attention: Legal Department
6950 Columbia Gateway Drive
Columbia, Maryland 21046

The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to PSTCREditor@magellanhealth.com.
### FDA-APPROVED INDICATIONS

<table>
<thead>
<tr>
<th>Drug</th>
<th>Manufacturer</th>
<th>Indication(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Corticosteroids</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| dexamethasone (Maxidex®)¹ | Alcon | ▪ Treatment of corticosteroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe  
▪ Corneal injury |
| dexamethasone sodium phosphate² | generic | ▪ Treatment of corticosteroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe  
▪ Corneal injury |
| difluprednate (Durezol®)³ | Alcon | ▪ Treatment of inflammation and pain associated with ocular surgery  
▪ Treatment of endogenous anterior uveitis |
| fluorometholone (FML®)⁴ | generic, Allergan | ▪ Treatment of corticosteroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe |
| fluorometholone (FML Forte®)⁵ | Allergan | ▪ Treatment of corticosteroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe |
| fluorometholone (FML S.O.P.®)⁶ | Allergan | ▪ Treatment of corticosteroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe |
| fluorometholone acetate (Flarex®)⁷ | Alcon | ▪ Treatment of corticosteroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe |
| loteprednol 0.5% gel, ointment (Lotemax®)⁸,⁹ | Bausch & Lomb | ▪ Treatment of post-operative inflammation and pain following ocular surgery |
| loteprednol 0.5% suspension (Lotemax®)¹⁰ | Bausch & Lomb | ▪ Treatment of corticosteroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe  
▪ Treatment of post-operative inflammation following ocular surgery |
| prednisolone acetate 1% (Omnipred®, Pred Forte®)¹¹,¹² | generic; Alcon, Allergan | ▪ Treatment of corticosteroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe  
▪ Treatment of corneal injury (Omnipred) |
| prednisolone acetate 0.12% (Pred Mild®)¹³ | Allergan | ▪ Treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns) |
| prednisolone sodium phosphate¹⁴ | generic | ▪ Treatment of inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe  
▪ Corneal injury |
| rimexolone (Vexol®)¹⁵ | Alcon | ▪ Treatment of anterior uveitis  
▪ Treatment of post-operative inflammation after ocular surgery |

Loteprednol ophthalmic suspension 0.2% (Alrex®) is indicated for the temporary relief of signs and symptoms of seasonal allergic conjunctivitis and is not included in this review.
FDA-Approved Indications (continued)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Manufacturer</th>
<th>Indication(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Corticosteroids – Intravitreal</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dexamethasone (Ozurdex®)¹⁶</td>
<td>Allergan</td>
<td>▪ Treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ Treatment of non-infectious uveitis affecting the posterior segment of the eye</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ Treatment of diabetic macular edema</td>
</tr>
<tr>
<td>fluocinolone 0.19 mg (Iluvien®)¹⁷</td>
<td>Alimera</td>
<td>▪ Treatment of diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure</td>
</tr>
<tr>
<td>fluocinolone 0.59 mg (Retisert®)¹⁸</td>
<td>Bausch &amp; Lomb</td>
<td>▪ Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye</td>
</tr>
<tr>
<td>triamcinolone acetonide (Triesence®)¹⁹</td>
<td>Alcon</td>
<td>▪ Treatment of sympathetic uveitis, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ Visualization during vitrectomy</td>
</tr>
<tr>
<td><strong>NSAIDs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>bromfenac (Prolensa™, BromSite™)²⁰,²¹,²²</td>
<td>generic, Bausch &amp; Lomb, Sun</td>
<td>▪ Treatment of post-operative inflammation and reduction of ocular pain secondary to cataract extraction/surgery</td>
</tr>
<tr>
<td>diclofenac²³</td>
<td>generic</td>
<td>▪ Treatment of post-operative inflammation secondary to cataract extraction</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ Temporary relief of pain and photophobia in patients undergoing corneal refractive surgery</td>
</tr>
<tr>
<td>flurbiprofen (Ocufen®)²⁴</td>
<td>generic, Allergan</td>
<td>▪ Inhibition of intraoperative miosis</td>
</tr>
<tr>
<td>ketorolac 0.4% (Acular LS®)²⁵</td>
<td>generic, Allergan</td>
<td>▪ Reduction of ocular pain, burning, and stinging after corneal refractive surgery</td>
</tr>
<tr>
<td>ketorolac 0.45% (Acuvail®)²⁶</td>
<td>Allergan</td>
<td>▪ Treatment of pain and inflammation following cataract surgery</td>
</tr>
<tr>
<td>nepafenac (Ilevro™, Nevanac®)²⁰,²⁸</td>
<td>Alcon</td>
<td>▪ Treatment of pain and inflammation associated with cataract surgery</td>
</tr>
</tbody>
</table>

*BromSite is approved for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery.

Ketorolac 0.5% ophthalmic solution (Acular®) is indicated for treatment of post-operative inflammation secondary to cataract extraction and temporary relief from ocular itching related to seasonal allergic conjunctivitis.²⁹

**OVERVIEW**

Uveitis is an inflammation of the middle layer of the eye or uvea, consisting of the iris, ciliary body, and choroid.³⁰,³¹ Uveitis may be caused by eye trauma, secondary to autoimmune diseases or infection, or may be idiopathic in nature.³² It may present as acute, chronic, or recurrent attacks, with unilateral pain or photophobia.³³ Aqueous cells and flare, due to cellular infiltration and protein exudation into the anterior chamber, are seen as spots and haze on slit-beam examination; both are signs of ocular inflammation. If left untreated, uveitis can lead to glaucoma, cataract, or retinal edema and ultimately
loss of vision. Initial treatment for uveitis typically includes ophthalmic corticosteroids (topical drops or intravitreal implant) to reduce pain and inflammation.

Temporal arteritis, affecting the superficial temporal arteries, is a systemic inflammatory vasculitis of unknown etiology that occurs in older individuals and can result in systemic, neurologic, and ophthalmologic complications.\(^{34}\) Permanent visual impairment is estimated in up to 20% of patients with the condition. Timely initiation of therapy may prevent irreversible damage, including blindness. The mainstay of therapy includes corticosteroids, which are typically prescribed for up to 2 years.

To ensure its transparency, the cornea is maintained in a dehydrated state by the pumping action of the endothelial cells controlled by Na+/K+-ATPase.\(^{35}\) Damage to the corneal endothelium may result in increased corneal thickness and ultimately corneal decompensation and loss of vision. Ophthalmic surgery, such as cataract extraction, generally results in moderate damage to the endothelium and a transient increase in corneal thickness. Endothelial cell count (density) and corneal thickness measurements are used to assess the degree of endothelial damage.

Ophthalmic anti-inflammatories, including corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs), are used to treat inflammatory conditions of the eye, including those due to trauma and surgery.

Topical corticosteroids are available in drops, gels, and ointments and are the standard of care for treating ophthalmic inflammation. Ophthalmic corticosteroids can, however, lead to side effects, such as increased intraocular pressure (IOP), cataract development, and increased risk of ocular infection.

Ophthalmic NSAIDs are primarily used during and after ophthalmic surgery.\(^{36}\) These agents reduce inflammation in the cornea and conjunctiva and help maintain papillary dilatation during surgery. Ophthalmic NSAIDs are used to control inflammation during surgery and in the first few days following surgery. Treatment with ophthalmic NSAIDs is not associated with the undesirable side effects as the ophthalmic corticosteroids as listed above. The American Academy of Ophthalmology (AAO) reports that postoperative topical regimens following cataract surgery vary among practitioners.\(^{37}\) There are no controlled studies establishing optimal regimens for the use of various topical agents, including topical corticosteroids and NSAIDs, following cataract surgery.

Corticosteroids that are administered via intravitreal injection and implantation are FDA approved to treat inflammatory conditions of the eye that are not related to injury or surgery, such as uveitis and macular edema. Diabetic macular edema (DME) is a microvascular complication of diabetes and is a leading cause of visual impairment and blindness in diabetic patients.\(^{38}\) DME is a progression of diabetic retinopathy and is caused by leakage of dilated capillaries and microaneurysms in the macular area.\(^{39}\) Intravitreal corticosteroids are administered by a licensed healthcare professional under aseptic conditions. As with the topically-applied ophthalmic products, intravitreal agents are associated with side effects including, cataract formation and elevated IOP. Injection-related side effects include retinal detachment, vitreous hemorrhage, bacterial endophthalmitis, and sterile endophthalmitis.

**PHARMACOLOGY**\(^{40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65}\)

Topical corticosteroids exert an anti-inflammatory action. Aspects of the inflammatory process, such as edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, deposition of collagen, scar formation, and fibroblastic proliferation, are suppressed. Topical corticosteroids are effective in acute inflammatory conditions of the conjunctiva, sclera, cornea, lids, iris, and anterior
segement of the globe, as well as in ocular allergic conditions. In ocular disease, route of administration depends on the site and extent of the condition being treated.

Ophthalmic NSAIDs have analgesic and anti-inflammatory activity. The mechanism of action is thought to be through the inhibition of cyclooxygenase enzymes, which are essential in prostaglandin production. Prostaglandins disrupt the blood-aqueous humor barrier, produce vasodilation, and increase vascular permeability, leukocytosis, and IOP.

During vitrectomy, dispersal of the water-insoluble triamcinolone acetonide (Triesence) particles within the vitreous chamber provides contrast to the transparent vitreous humor and membranes.

PHARMACOKINETICS

Highly potent corticosteroids include dexamethasone acetate, difluprednate, prednisolone acetate, and prednisolone phosphate; moderate potency steroids are rimexolone, dexamethasone phosphate, and fluorometholone acetate. The efficacy of a topical corticosteroid is based on potency, vehicle, drug concentration, duration of action, contact time, and ocular penetration. Most topically-applied corticosteroids penetrate the eye via the cornea. In general, acetate and alcohol forms are more lipophilic and lead to longer contact time and better penetration due to the lipid nature of the cornea, while the phosphate form is more hydrophilic and leads to decreased corneal penetration. In addition, presence of intraocular inflammation may result in increased absorption.

The duration of effect of dexamethasone intravitreal implant (Ozurdex) lasts approximately 1 to 3 months. The fluocinolone acetonide intravitreal implants are designed to deliver drug over approximately 30 months (Retisert) and 36 months (Iluvien).

Intravitreal administration allows a corticosteroid dose to be delivered over prolonged period of time and allows the dose to bypass the blood–retinal barrier.

Due to the topical nature of this drug class, systemic absorption for most products is below detectable levels. Ketorolac (Acular, Acular LS, Acuvail) does achieve measurable systemic levels, but there is no clinical impact. Nepafenac (Ilevro, Nevanac) is a prodrug that is metabolized via ocular tissue hydrolases to the active NSAID, amfenac. Low systemic levels of nepafenac and amfenac have been observed after topical administration to the eye. Nepafenac has been shown to penetrate the cornea more rapidly and provides more complete (80% versus 50%) and longer lasting inhibition of prostaglandin synthesis (> 6 hours versus 3 hours) and vascular permeability (8 hours versus 4 hours) than diclofenac. After topical instillation, systemic levels of bromfenac (generic, Prolensa, BromSite) and diclofenac remain below the level of detection.

CONTRAINDICATIONS/WARNINGS

Ophthalmic corticosteroids, including dexamethasone (Ozurdex) and fluocinonide (Iluvien, Retisert) intravitreal implants, are contraindicated in patients with viral (epithelial herpes simplex keratitis, vaccinia, varicella), mycobacterial, or fungal infections of the eye. The label for triamcinolone intravitreal suspension (Triesence) contains warnings for the use of corticosteroids in general and the risk of infection due to fungi or viruses; it should be used with caution in patients with ocular herpes simplex and should not be used in those with active infection. Triamcinolone is contraindicated in patients with systemic fungal infections.
Dexamethasone intravitreal implant (Ozurdex) and fluocinonide implant (Iluvien) are contraindicated in patients with glaucoma who have cup to disc ratios of greater than 0.8. Dexamethasone intravitreal implant is also contraindicated in patients with a rupture of the posterior lens capsule.

Prolonged use of ophthalmic corticosteroids, including intravitreal agents, may cause ocular hypertension and/or glaucoma, defects in visual acuity and fields of vision, posterior subcapsular cataract formation, and secondary ocular infections. Perforations have occurred in patients with thinning of the cornea or sclera.

The products in this review are contraindicated in patients with known hypersensitivity to any component of the product. Bromfenac (Prolensa) contains sodium sulfite which may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes, particularly in those with asthma. As with all NSAIDs, cross-hypersensitivity in patients with aspirin and other NSAID-hypersensitivities is possible; caution should be used in such patients. There have been reports of bronchospasm or exacerbation of asthma associated with the use of ketorolac tromethamine ophthalmic solution in patients who either have a known hypersensitivity to aspirin/NSAID or a past medical history of asthma.

Surgical complications have been associated with intravitreal products. Intravitreally administered corticosteroid implants and suspensions have been associated with endophthalmitis, eye inflammation, increased IOP, and retinal detachments. Following implantation of fluocinolone (Iluvien, Retisert), patients may experience an immediate and temporary decrease in visual acuity lasting 1 to 4 weeks post-operatively. Intravitreal implants may migrate to the anterior chamber if the posterior lens capsule is not intact; the fluocinolone implant (Retisert) has been associated with separation of implant components.

Refractive stability of patients undergoing corneal refractive procedures and treatment with diclofenac usage has not been well established. There have been reports that ophthalmic NSAIDs may cause increased bleeding of ocular tissues when used in this setting; therefore, patients should be monitored for a year following use in this setting. Use with caution in patients at increased risk of bleeding.

In March 2016, the Food and Drug Administration (FDA) warned the public that eye drop bottles that have loose plastic safety seals or tamper-evident rings (also known as a collar or band) below the bottle cap may cause eye injuries during administration if the seal/ring falls onto the eye. All affected products will require a change in the packaging design.

Precautions

NSAIDs may cause keratitis. In some patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration, or corneal perforation. These events may be sight-threatening. Patients with evidence of corneal epithelial breakdown should discontinue use of topical NSAIDs immediately and should be closely monitored. Patients who might be at risk for complications include those with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time. Using ophthalmic NSAIDs beyond the 14 days may increase a patient’s risk of severe corneal adverse events.

Topical NSAIDs and topical corticosteroids may slow or delay healing and concomitant use of topical NSAIDs and topical steroids may increase this risk.
Bromfenac (generic, Prolensa, BromSite), ketorolac (Acular, Acular LS, Acuvail) and nepafenac (Illevro, Nevanac) should not be administered while wearing contact lenses. Except for the use of a bandage hydrogel soft contact lens during the first 3 days following refractive surgery, diclofenac 0.1% solution should not be used by patients currently wearing soft contact lenses.

Precautions for triamcinolone intravitreal suspension include elevated blood pressure, salt and water retention, hypokalemia, gastrointestinal perforation, behavioral and mood disturbances, decreased bone density, and weight gain.

Use of the same bottle for both eyes is not recommended with topical eye drops that are used in association with surgery.

**DRUG INTERACTIONS**

Due to the topical nature of these anti-inflammatory agents, drug interaction studies have not been systematically performed. Nepafenac (Nevanac) has been investigated for potential impact on the cytochrome P450 system; no potential impact was identified.

When ophthalmic medications need to be used concurrently, they should be administered at least 5 minutes apart.
### ADVERSE EFFECTS

<table>
<thead>
<tr>
<th>Drug</th>
<th>Transient burning/stinging</th>
<th>Ocular irritation</th>
<th>Corneal edema</th>
<th>Vision change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Corticosteroids</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dexamethasone (Maxidex)(^{159})</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
<td>reported</td>
</tr>
<tr>
<td>dexamethasone sodium phosphate(^{160})</td>
<td>reported</td>
<td>reported</td>
<td>nr</td>
<td>reported</td>
</tr>
<tr>
<td>difluprednate (Durezol)(^{161})</td>
<td>nr</td>
<td>1-5</td>
<td>2-5</td>
<td>1-5</td>
</tr>
<tr>
<td>fluorometholone (FML)(^{162})</td>
<td>reported</td>
<td>reported</td>
<td>nr</td>
<td>reported</td>
</tr>
<tr>
<td>fluorometholone (FML Forte)(^{163})</td>
<td>reported</td>
<td>reported</td>
<td>nr</td>
<td>reported</td>
</tr>
<tr>
<td>fluorometholone (FML S.O.P.)(^{164})</td>
<td>nr</td>
<td>reported</td>
<td>nr</td>
<td>nr</td>
</tr>
<tr>
<td>fluorometholone acetate (Flarex)(^{165})</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
<td>reported</td>
</tr>
<tr>
<td>loteprednol gel (Lotemax)(^{166})</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
</tr>
<tr>
<td>loteprednol ointment (Lotemax)(^{167})</td>
<td>nr</td>
<td>nr</td>
<td>4-5</td>
<td>nr</td>
</tr>
<tr>
<td>loteprednol suspension (Lotemax)(^{168})</td>
<td>5-15</td>
<td>&lt; 5</td>
<td>&lt; 5</td>
<td>5-15</td>
</tr>
<tr>
<td>prednisolone acetate (Omnipred, Pred Forte)(^{169,170})</td>
<td>nr</td>
<td>reported</td>
<td>nr</td>
<td>nr</td>
</tr>
<tr>
<td>prednisolone acetate (Pred Mild)(^{171})</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
<td>reported</td>
</tr>
<tr>
<td>prednisolone sodium phosphate(^{172})</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
<td>reported</td>
</tr>
<tr>
<td>rimexolone (Vexol)(^{173})</td>
<td>1-5</td>
<td>1-5</td>
<td>&lt; 1</td>
<td>1-5</td>
</tr>
<tr>
<td><strong>Corticosteroids - Intravitreal</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dexamethasone (Ozurdex)(^{174})</td>
<td>nr</td>
<td>7</td>
<td>nr</td>
<td>nr</td>
</tr>
<tr>
<td>fluocinolone (Iluvien)(^{175})</td>
<td>nr</td>
<td>8</td>
<td>4</td>
<td>5-29</td>
</tr>
<tr>
<td>fluocinolone (Retisert)(^{176})</td>
<td>nr</td>
<td>10-40</td>
<td>50-90</td>
<td>10-40</td>
</tr>
<tr>
<td>triamcinolone acetonide (Triesence)(^{177})</td>
<td>nr</td>
<td>&lt; 2</td>
<td>nr</td>
<td>&lt; 2</td>
</tr>
</tbody>
</table>
**Adverse Effects (continued)**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Transient burning/stinging</th>
<th>Ocular irritation</th>
<th>Corneal edema</th>
<th>Vision change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NSAIDs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>bromfenac 0.07% (Prolensa)</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
<td>3-8</td>
</tr>
<tr>
<td>bromfenac 0.075% (BromSite)</td>
<td>nr</td>
<td>1-8</td>
<td>nr</td>
<td></td>
</tr>
<tr>
<td>bromfenac 0.09%</td>
<td>2-7</td>
<td>2-7</td>
<td>nr</td>
<td>nr</td>
</tr>
<tr>
<td>diclofenac</td>
<td>15</td>
<td>&lt; 5</td>
<td>&lt; 5</td>
<td>&lt; 5</td>
</tr>
<tr>
<td>flurbiprofen (Ocufen)</td>
<td>reported</td>
<td>reported</td>
<td>nr</td>
<td>nr</td>
</tr>
<tr>
<td>ketorolac (Acular LS)</td>
<td>20-40</td>
<td>1-10</td>
<td>1-10</td>
<td>nr</td>
</tr>
<tr>
<td>ketorolac (Acuvail)</td>
<td>nr</td>
<td>1-6</td>
<td>1-6</td>
<td>1-6</td>
</tr>
<tr>
<td>nepafenac (Ilevro, Nevanac)</td>
<td>reported</td>
<td>1-5</td>
<td>1-5</td>
<td>5-10</td>
</tr>
</tbody>
</table>

Adverse effects are reported as a percentage. Adverse effects data are obtained from prescribing information and are not meant to be comparative or all inclusive. nr = not reported.

The most common ocular adverse event reported in clinical studies for loteprednol ointment was anterior chamber inflammation at a rate of approximately 25%. In studies with loteprednol gel, this was reported in 5% of subjects.187

Benzalkonium chloride is a preservative used in many ophthalmic preparations; however it can cause a dose- and duration-dependent breakdown of the corneal epithelium and increased absorption. The following products contain benzalkonium chloride: **bromfenac (BromSite)**, dexamethasone (Maxidex), dexamethasone sodium phosphate, fluorometholone (FML, FML Forte), fluorometholone acetate (Flarex), loteprednol (Lotemax suspension, gel), ketorolac (Acular, Acular LS), nepafenac (Ilevro, Nevanac), prednisolone (Omnipred), prednisolone acetate (Pred Mild), prednisolone sodium phosphate, and rimexolone (Vexol).188,189,190 Flurbiprofen (Ocufen) contains thimerosal, which can cause allergic contact conjunctivitis.191,192 Sorbic acid, which may cause less damage and irritation to the ocular surface, is the preservative in difluprednate (Durezol).193 Fluorometholone (FML S.O.P.) uses phenylmercuric acetate; ocular side effects are rare, but mercurialentis (deposition of pigment on the lens) has been reported.194 Ketorolac (Acuvail) does not contain any preservative.

The most common adverse reactions following use of bromfenac 0.07% (Prolensa), reported in 3% to 8% of patients, include anterior chamber inflammation, foreign body sensation, eye pain, and photophobia.195 The most common adverse reactions following use of bromfenac 0.075% (BromSite), reported in 1% to 8% of patients, include anterior chamber inflammation, headache, vitreous floaters, iritis, eye pain and ocular hypertension.196

The most common adverse effects reported with fluocinonide intravitreal implant (Iluvien) are cataracts (82%) and myodesopsia (floaters; 21%). With fluocinonide intravitreal implant (Retisert) and triamcinolone suspension (Triesence) the most common adverse effects are cataracts and increased
ocular pressure; and with dexamethasone implant (Ozurdex) are increased ocular pressure (25%) and conjunctival hemorrhage (22%).

Results from clinical studies indicate that ophthalmic NSAIDs have no significant effect on IOP; however, after cataract surgery, changes in IOP may occur. In clinical studies with diclofenac, elevated IOP following cataract surgery was reported in approximately 15% of patients undergoing cataract surgery. Studies reported increased ocular pressure following cataract surgery in 5-10% of patients treated with nepafenac 0.1% suspension (Nevanac). In the MEAD clinical study, increased IOP of ≥ 10 mm Hg was reported in 27.7% of patients with diabetic macular edema who were treated with dexamethasone 0.7 mg implant (Ozurdex).

In a 3-month, double-masked trial, a similar safety profile was observed for difluprednate (Durezol) and prednisolone acetate ophthalmic suspension 1%, in 79 pediatric patients, 0 to 3 years of age, in the treatment of inflammation following cataract surgery.

In 54 children who underwent surgery for bilateral symmetric strabismus, rimexolone and fluorometholone were compared for anti-inflammatory efficacy and ocular hypertension. One eye was randomized to receive rimexolone 1% and the other eye received fluorometholone 0.1%; both medications were administered 4 times daily for 4 weeks. IOP increased significantly in both treatment groups, but the mean peak IOP was significantly higher with rimexolone than fluorometholone (19.7 mm Hg versus 17.6 mm Hg, respectively; p<0.001). More children in the rimexolone group had no conjunctival erythema on days 13 and 20 (p=0.03). Authors concluded that IOP should be monitored in children receiving rimexolone therapy on a regular basis.

**SPECIAL POPULATIONS**

**Pediatrics**

Safety and efficacy of fluocinolone (Iluvien) and dexamethasone (Ozurdex) implants have not been established in pediatric patients, while safety and effectiveness of fluocinolone intravitreal implant (Retisert) have not been established in patients younger than 12 years. The labeling for triamcinolone intravitreal suspension (Triesence) states that safety and efficacy of corticosteroids is similar in pediatric and adult populations.

Fluorometholone (FML, FML Forte, FML S.O.P.) has been studied in children ages 2 years and older. The safety and efficacy of other corticosteroid products in this class have not been studied, but dexamethasone drops and prednisolone are reportedly safe in children, in general.

Safety and effectiveness in pediatric patients have not been established in children for bromfenac (generic, Prolensa, BromSite), diclofenac, flurbiprofen sodium (Ocufen), ketorolac tromethamine 0.45% solution (Acuvail), and loteprednol (Lotemax gel, ointment, suspension). Nepafenac (Ilevro, Nevanac) has not been studied in children less than 10 years of age. Ketorolac products (Acular, Acular LS) have been approved for use in children age 3 years and older.

Pregnancy

With the exception of triamcinolone (Triesence), which is Pregnancy Category D, agents in this class assigned a Pregnancy Category are Pregnancy Category C. Due to the known effects of NSAIDs and the
prostaglandin biosynthesis-inhibiting drugs on the fetal cardiovascular system, including the closure of ductus arteriosus, the use of many of these ophthalmic NSAIDs during late pregnancy should be avoided. Bromfenac (BromSite) has not been assigned a Pregnancy Category based on the Pregnancy and Lactation Labeling Rule (PLLR). There are no adequate and well-controlled studies of bromfenac 0.075% in pregnant women to inform any drug associated risks; its risks are expected to be similar to other ocular NSAIDs with minimal systemic absorption, as described above. The labeling for bromfenac ophthalmic solution 0.07% (Prolensa) and ketorolac 0.4% solution (Acular LS) have been updated to conform to the PLLR; studies in pregnant women are lacking and these agents should be used during pregnancy only if potential benefit justifies the potential risk to the fetus.
### DOSAGES

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Corticosteroids</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dexamethasone 0.1% suspension (Maxidex)&lt;sup&gt;239&lt;/sup&gt;</td>
<td>Apply 1 to 2 drops to the conjunctival sac of the affected eye(s) every 4 to 6 hours; in severe disease, may administer drops hourly, tapering to discontinuation as the inflammation subsides</td>
<td>5 mL</td>
</tr>
<tr>
<td>dexamethasone sodium phosphate 0.1% solution&lt;sup&gt;240&lt;/sup&gt;</td>
<td>Apply 1 to 2 drops to the conjunctival sac of the affected eye(s) every hour during the day and every 2 hours at night; reduce frequency to every 4 hours once a favorable response occurs</td>
<td>5 mL</td>
</tr>
</tbody>
</table>
| difluprednate 0.05% emulsion (Durezol)<sup>241</sup> | **Inflammation and pain with ocular surgery:** Apply 1 drop to the conjunctival sac of the affected eye(s) 4 times daily beginning 24 hours after surgery and continuing for 2 weeks post-op, then twice daily for another week, then taper based on response  
**Endogenous anterior uveitis:** Apply 1 drop to the conjunctival sac of the affected eye 4 times daily for 14 days followed by tapering, as clinically indicated | 5 mL |
| fluorometholone 0.1% suspension (FML)<sup>242</sup> | Apply 1 drop to the conjunctival sac of the affected eye(s) 2 to 4 times daily (may be used every 4 hours during initial 24 to 48 hours) | 5, 10, 15 mL |
| fluorometholone 0.25% suspension (FML Forte)<sup>243</sup> | Apply 1 drop to the conjunctival sac of the affected eye(s) 2 to 4 times daily (may be used every 4 hours during initial 24 to 48 hours) | 5, 10 mL |
| fluorometholone 0.1% ointment (FML S.O.P.)<sup>244</sup> | Apply half-inch ribbon to the conjunctival sac of the affected eye(s) 1 to 3 times daily (may be used every 4 hours during initial 24 to 48 hours) | 3.5 g tube |
| fluorometholone acetate 0.1% suspension (Flarex)<sup>245</sup> | Apply 1 to 2 drops to the conjunctival sac of the affected eye(s) 4 times daily (may be used as 2 drops every 2 hours during initial 24 to 48 hours) | 5 mL |
| loteprednol 0.5% gel (Lotemax)<sup>246</sup> | Apply 1 to 2 drops into the conjunctival sac of the affected eye(s) 4 times daily starting 24 hours after surgery for 2 weeks | 5 g |
| loteprednol 0.5% ointment (Lotemax)<sup>247</sup> | Apply half-inch ribbon into the conjunctival sac of the affected eye(s) 4 times daily starting 24 hours after surgery for 2 weeks | 3.5 g tube |
| loteprednol 0.5% suspension (Lotemax)<sup>248</sup> | **Anti-inflammatory:** Apply 1 to 2 drops 4 times daily (up to every hour during the first week, if necessary)  
**Cataract surgery:** Apply 1 to 2 drops 4 times a day starting 24 hours after surgery for 2 weeks | 5, 10, 15 mL |
| prednisolone acetate 1% suspension (Omnipred, Pred Forte)<sup>249, 250</sup> | Omnipro: Apply 2 drops to the affected eye(s) 4 times daily  
Pred Forte: Apply 1 to 2 drops into the conjunctival sac of the affected eye(s) 2 to 4 times daily (may increase dosing frequency during the initial 24 to 48 hours if needed) | 1, 5, 10, 15 mL |
| prednisolone acetate 0.12% suspension (Pred Mild)<sup>251</sup> | Apply 1 to 2 drops to the conjunctival sac of the affected eye(s) 2 to 4 times daily (may increase dosing frequency during the initial 24 to 48 hours if needed) | 5, 10 mL |
| prednisolone sodium phosphate 1% solution<sup>252</sup> | Apply 1 to 2 drops to the conjunctival sac of the affected eye(s) every hour during the day and every 2 hours at night; reduce frequency once a favorable response occurs | 5, 10, 15 mL |
| rimexolone 1% solution (Vexol)<sup>253</sup> | **Anterior uveitis:** Apply 1 to 2 drops every hour (while awake) for 1 week, then every 2 hours for the second week, then taper off until resolved  
**Ocular surgery:** Apply 2 drops 4 times a day starting 24 hours after surgery for a duration of 2 weeks | 5, 10 mL |
### Dosages (continued)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Corticosteroids - Intravitreal</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dexamethasone (Ozurdex)</td>
<td>Implanted intravitreally by healthcare provider</td>
<td>0.7 mg implant</td>
</tr>
<tr>
<td>fluorocinolone (Iluvien)</td>
<td>Surgically implanted inferior to the optic disc and posterior to the equator of the eye; designed to release drug over 36 months</td>
<td>0.19 mg implant</td>
</tr>
<tr>
<td>fluorocinolone (Retisert)</td>
<td>Surgically implanted into posterior segment of the affected eye(s); designed to release drug over 30 months</td>
<td>0.59 mg implant</td>
</tr>
<tr>
<td>triamcinolone acetonide (Triesence)</td>
<td>Inflammation: 4 mg intravitreally Visualization: 1 to 4 mg intravitreally</td>
<td>40 mg/1 mL vial</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>NSAIDs</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>bromfenac 0.07% solution (Prolensa)</td>
</tr>
<tr>
<td>bromfenac 0.075% solution (BromSite)</td>
</tr>
<tr>
<td>bromfenac 0.09% solution</td>
</tr>
<tr>
<td>diclofenac 0.1% solution</td>
</tr>
<tr>
<td>flurbiprofen sodium 0.03% solution (Ocufen)</td>
</tr>
<tr>
<td>ketorolac tromethamine 0.4% solution (Acular LS)</td>
</tr>
<tr>
<td>ketorolac tromethamine 0.45% solution (Acuvail)</td>
</tr>
<tr>
<td>nepafenac 0.3% suspension (Ilevro)</td>
</tr>
<tr>
<td>nepafenac 0.1% suspension (Nevanac)</td>
</tr>
</tbody>
</table>
CLINICAL TRIALS

Articles were identified through searches performed on PubMed and review of information sent by manufacturers. Search strategy included the ophthalmic use of all drugs in this class. Randomized controlled comparative trials for ophthalmic FDA-approved indications are considered the most relevant in this category. Studies included for analysis in the review were published in English, performed with human participants, and randomly allocated participants to comparison groups. In addition, studies must contain clearly stated, predetermined outcome measure(s) of known or probable clinical importance, use data analysis techniques consistent with the study question and include follow-up (endpoint assessment) of at least 80% of participants entering the investigation. Despite some inherent bias found in all studies including those sponsored and/or funded by pharmaceutical manufacturers, the studies in this therapeutic class review were determined to have results or conclusions that do not suggest systematic error in their experimental study design. While the potential influence of manufacturer sponsorship and/or funding must be considered, the studies in this review have also been evaluated for validity and importance. Several studies were performed in the perioperative setting which is not applicable to the outpatient utilization. These studies were excluded from this review.

There are no published comparative trials of intravitreal corticosteroids.

Topical Corticosteroids

difluprednate 0.05% (Durezol) versus prednisolone acetate 1%

In a multicenter, randomized, contralateral-eye, double-masked trial, the effects of difluprednate 0.05% and prednisolone acetate 1% on corneal thickness and visual acuity after cataract surgery were compared on 52 patients (104 eyes) that underwent bilateral phacoemulsification.267 For each patient, the first eye randomly received difluprednate 0.05% or prednisolone acetate 1%; the other eye received the alternative. Before surgery, 7 doses were administered over 2 hours; 3 additional doses were given after surgery, before discharge. For the remainder of the day, corticosteroids were administered every 2 hours, then 4 times daily during Week-1, and twice daily during Week-2. On Day-1 after surgery, corneal thickness was 33 μm less in difluprednate-treated eyes (p=0.026), uncorrected and best corrected visual acuity were significantly better with difluprednate than prednisolone by 0.093 logMAR lines (p=0.041) and 0.134 logMAR lines (p<0.001), respectively. Endothelial cell density was 195.52 cells/mm² higher in difluprednate-treated eyes at day 30 (p<0.001). Retinal thickness at Day-15 was 7.74 μm less in difluprednate-treated eyes (p=0.011).

loteprednol suspension (Lotemax) versus prednisolone acetate

In 2 studies of acute anterior uveitis, loteprednol 0.5% suspension was compared to prednisolone acetate 1% for reduction in ocular signs and symptoms. Both studies were parallel, randomized, double-blind, active controlled comparisons.268 In the first study, treatment was administered 8 times daily and lasted for 42 days in 70 patients. The second study was 28 days in duration with initial treatment given 16 times daily in 175 patients. At the end of the first trial, 74% of loteprednol patients and 88% of prednisolone patients achieved resolution. The difference was not significant. In the second study, the 2 groups were not different with resolution rates of 72% for loteprednol and 87% for prednisolone groups. Elevated IOP was observed more frequently in the prednisolone group. This difference in resolution rates between loteprednol and prednisolone acetate appears in the prescribing
information for loteprednol. The use of a more potent corticosteroid than loteprednol, such as prednisolone acetate 1%, is suggested for the treatment of anterior uveitis.\textsuperscript{269}

\textit{rimexolone (Vexol) versus prednisolone acetate}

Rimexolone 1% suspension and prednisolone acetate 1% were compared in 48 patients undergoing cataract extraction with phacoemulsification followed by posterior chamber intraocular lens implantation in a randomized, double-blind trial.\textsuperscript{270} Both therapies were administered 4 times daily for 15 days. Patients were examined on Days-1, -3, -7, and -15. Efficacy was similar in both groups as defined by anterior chamber cells, anterior chamber flare, and conjunctival hyperemia. IOP measurements were similar in both groups.

Two multicenter studies compared the efficacy and safety of rimexolone 1% suspension and prednisolone acetate 1% in patients with uveitis.\textsuperscript{271} Administration of each drug was every 2 hours initially with a gradual taper over 4 weeks. No significant differences in response rates were found between the 2 groups at the various evaluation periods or at the end of treatment. Prednisolone patients were found to have a higher likelihood of IOP elevation in both studies.

A randomized, triple-blinded, parallel comparison was completed evaluating rimexolone 1% and prednisolone 1% in 78 patients with acute, chronic, or recurrent anterior uveitis.\textsuperscript{272} Patients instilled 1 or 2 drops of the assigned drug hourly while awake for the first week, then every 2 hours during the second week, then 4 times daily in the third week, then following a taper to complete 4 weeks of therapy. Anterior chamber cells and flare reactions were monitored periodically during the study. Overall clinical efficacy was similar between the 2 treatments. The IOP was also similar during the study; however, 3 patients receiving rimexolone 1% and one patient receiving prednisolone 1% had elevated IOP during the study.

\textit{dexamethasone intravitreal implant (Ozurdex)}

A study included 30 eyes of 30 patients to evaluate the efficacy and safety of dexamethasone intravitreal implant in patients with diabetic macular edema that was resistant to prior intravitreal bevacizumab therapy.\textsuperscript{273} At 1 and 3 months, the mean best corrected visual acuity (BCVA, logMAR) increased from 0.56 ± 0.38 to 0.41 (p<0.001), and 0.44 (p=0.008), respectively. At 1, 3, and 6 months, the mean central foveal thickness (CFT) decreased significantly from a baseline of 517 \( \mu \)m to 290 \( \mu \)m (p<0.001) at month 1, but significantly increased to 314 \( \mu \)m (p<0.003) and 411 \( \mu \)m (p=0.01) at months 3 and 6, respectively. Mean cub volume (MCV) significantly increased and BCVA significantly decreased from months 3 to 6. IOP measures were significantly higher at week 1 and months 1 and 3. Macular edema recurrence occurred in 25 eyes at 6 months. Researchers concluded that although dexamethasone intravitreal implant was safe and effective in treating patients resistant to bevacizumab, its efficacy decreased after 3 months.

**Topical NSAIDs**

\textit{diclofenac versus flurbiprofen (Ocufen)}

In a double-blind trial, 43 patients undergoing cataract extraction were randomized to diclofenac sodium 0.1% or flurbiprofen 0.03%.\textsuperscript{274} The assigned medication was instilled every 6 hours for 3 doses prior to surgery, then 4 drops over 90 minutes just prior to surgery. After surgery, patients administered the assigned medication 4 times daily for 3 to 6 weeks. Patients were examined 1, 3, and
6 weeks post-operatively. There were no statistically significant differences between the treatment groups for conjunctival hyperemia, corneal surface changes, IOP, or anterior chamber inflammation.

**diclofenac versus ketorolac (Acular)**

In a double-masked, randomized trial during the post-operative period of cataract extraction and implantation of an intraocular lens, a total of 120 patients were treated with either diclofenac 0.1% solution or ketorolac tromethamine 0.5% solution 4 times daily for 30 days. Treatment began the first post-operative day after surgery. Objective measurements of inflammation and toxicity were made at 3 post-operative visits. The anti-inflammatory effects were similar at all 3 post-operative visits. Both treatments were equally tolerated.

In a long-term follow-up to the above study, the primary endpoint was to evaluate the incidence of post-operative posterior opacification. Patients were followed for 3 years and received yttrium-aluminum-garnet (YAG) laser capsulotomies and were evaluated for any existing post-operative posterior opacification. The incidence of post-operative posterior opacification and YAG capsulotomies were similar (12% in each treatment group). Adverse effects from therapy were also similar in both groups.

In a double-blind, randomized study, diclofenac 0.1% solution and ketorolac 0.5% solution were compared in 30 patients for efficacy in relieving corneal pain after refractive surgery. Patients underwent radial keratotomy and were monitored for post-operative pain and instillation comfort. Both diclofenac and ketorolac were similarly effective in reducing ocular pain and had similar comfort on instillation (p=0.29).

**ketorolac 0.5% (Acular) versus ketorolac 0.4% (Acular LS)**

The 2 formulations of ketorolac tromethamine 0.4% and 0.5% ophthalmic solutions were compared for effectiveness and patient tolerance in 40 patients undergoing phacoemulsification and lens implantation. In a double-masked study, patients were randomized to receive 1 of the 2 strengths of ketorolac starting 15 minutes prior to surgery. After surgery, patients administered 1 drop 4 times daily for 1 week, then twice daily for 3 weeks. Patients were examined on Day-1, -7, and -30. On Day-1, more patients reported foreign body sensation or stinging and burning in the ketorolac 0.5% group (70%) than the ketorolac 0.4% group (40%; p<0.05). There were no significant differences between the 2 groups for best-corrected visual acuity, IOP, slit-lamp assessment of cells, or cell/flare measured using the laser cell/flare meter.

**ketorolac (Acular) versus loteprednol suspension (Lotemax)**

In a randomized, double-blind trial looking at controlling inflammation after cataract surgery, 60 patients were randomized to receive ketorolac tromethamine 0.5% or loteprednol etabonate 0.5% suspension 4 times a day starting 24 hours after surgery. There was no statistically significant difference in any measurement of post-operative inflammation between the 2 groups measured by external slit-lamp examination on post-operative days 1, 4, 7, and 30.

**ketorolac (Acular LS) versus nepafenac (Nevanac)**

A randomized study compared the efficacy of ketorolac tromethamine 0.4% and nepafenac 0.1% eye drops for prophylaxis of cystoid macular edema (CME) after small-incision cataract extraction. The incidence and severity of CME were evaluated by retinal foveal thickness on optical coherence...
tomography (OCT) after 1, 4 and 12 weeks in patients who were randomized to ketorolac tromethamine 0.4%, nepafenac 0.1%, or placebo. One hundred and twenty-six eyes of 126 patients were included were evaluated. The between-group differences in visual outcomes, central corneal thickness and endothelial cell density, or measurements performed by spectral-domain OCT were not statistically significant.

**ketorolac (Acular) versus prednisolone acetate**

In a double-blind trial, 59 patients requiring cataract extraction were randomized to receive either ketorolac tromethamine 0.5% solution or prednisolone acetate 1%. Treatment was administered according to the following schedule: 1 to 2 drops 4 times daily for 1 week; 3 times daily for the second week; 2 times daily for the third week; and once daily for the fourth week. At day 28, both treatments produced comparable reductions in intraocular inflammation and pain after cataract surgery and were well tolerated by patients. No adverse events were reported.

**ketorolac (Acular) versus rimexolone (Vexol)**

Ketorolac tromethamine 0.5% and rimexolone 1% were compared in 2 small studies evaluating the control of inflammation following cataract surgery in 36 patients. Patients were randomized to either agent in a double-blind manner, and the assigned drops were administered 4 times daily starting 24 hours post-operatively. No difference was found between the 2 agents for the post-operative inflammation at any time period. No difference was noted in the IOP between the groups.

**nepafenac 0.3% (Ilevro) versus nepafenac 0.1% (Nevanac) versus placebo**

In 2 double-masked, randomized clinical trials, nepafenac ophthalmic suspensions 0.3% and 0.1% were compared to vehicle dosed daily starting 1 day prior to cataract surgery, continued on the day of surgery, and for the first 2 weeks postoperatively. Nepafenac suspension showed better clinical efficacy compared to its vehicle. In the first study, inflammation resolved at postoperative day 14 in 65% of nepafenac ophthalmic suspension 0.3% patients, in 32% of vehicle patients, and in 67% of nepafenac ophthalmic suspension 0.1% patients (95% CI, 33% [26-40]) for nepafenac ophthalmic suspension 0.3% and vehicle. Ocular pain at day 14 resolved in 86% of nepafenac 0.3% patients, 46% of placebo patients, and 87% of nepafenac 0.1% patients (95% CI 40% [32-47]) for nepafenac ophthalmic suspension 0.3% and vehicle. In the second study, nepafenac 0.3% (n=540) resolved inflammation (postoperative day 14) versus vehicle (n=268) in 61% and 24% of patients, respectively. Ocular pain resolved in 84% and 38% of nepafenac 0.3% and vehicle groups, respectively.

**SUMMARY**

Ophthalmic corticosteroids have long been used as first-line therapy for the treatment of ophthalmic inflammatory conditions prior to the increased use of ophthalmic NSAIDs. The ophthalmic NSAIDs offer equivalent anti-inflammatory efficacy for post-operative inflammation. Ophthalmic corticosteroids have the potential for long-term adverse events, such as increased intraocular pressure (IOP), cataract formation and increased risk of ocular infection, but studies comparing ophthalmic corticosteroids to ophthalmic NSAIDs have not shown clinical differences in adverse event profiles when treatment duration is 30 days or less. There are no data to suggest a significant advantage for any one product in either subclass in terms of clinical effectiveness or adverse effect profile, nor are there data that show a difference between agents in different subclasses.
Products with invasive intravitreal administration (Iluvien, Retisert, Triesence, Ozurdex) are available and injected by a licensed healthcare professional. These agents (Ozurdex, Retisert, Triesence) are approved to treat uveitis, typically when topical therapy fails. In addition, dexamethasone (Ozurdex), and fluocinolone (Iluvien) implants are indicated to treat diabetic macular edema, dexamethasone implant is also indicated to treat macular edema following branch/central retinal vein occlusion.

REFERENCES

1 Maxidex [package insert]. Fort Worth, TX; Alcon; December 2015.
3 Durezol [package insert]. Fort Worth TX; Alcon; July 2016.
4 FML [package insert]. Irvine, CA; Allergan; February 2013.
5 FML Forte [package insert]. Irvine, CA; Allergan; February 2013.
6 FML S.O.P. [package insert]. Irvine, CA; Allergan; February 2005.
7 Flarex [package insert]. Fort Worth, TX; Alcon; December 2006.
8 Lotemax ointment [package insert]. Tampa, FL; Bausch & Lomb; April 2011
9 Lotemax gel [package insert]. Tampa, FL; Bausch & Lomb; September 2012.
10 Lotemax suspension [package insert]. Tampa, FL; Bausch & Lomb; August 2013.
11 Omnipred [package insert]. Fort Worth, TX; Alcon; October 2007.
12 Pred Forte [package insert]. Irvine, CA; Allergan; August 2013.
13 Pred Mild [package insert]. Irvine, CA; Allergan; April 2014.
15 Voxel [package insert]. Fort Worth, TX; Alcon; February 2012.
16 Ozurdex [package insert]. Irvine, CA; Allergan; September 2014.
19 Triesence [package insert]. Fort Worth, TX; Alcon; November 2007.
21 Prolensa [package insert]. Tampa, FL; Bausch & Lomb; June 2016.
22 BromSite [package insert]. Cranbury, NJ; Sun; April 2016.
23 Voltaren [package insert]. Duluth, GA; Novartis; September 2012.
24 Ocufen [package insert]. Irvine, CA; Allergan; July 2012.
26 Acuvail [package insert]. Irvine, CA; Allergan; December 2014.
27 Iлевро [package insert]. Fort Worth, TX; Alcon; February 2014.
28 Nevanac [package insert]. Fort Worth, TX; Alcon; July 2011.
29 Acular [package insert]. Irvine, CA; Allergan; June 2012.
40 Maxidex [package insert]. Fort Worth, TX; Alcon; December 2015.
42 Durezol [package insert]. Fort Worth TX; Alcon; July 2016.
44 FML [package insert]. Irvine, CA; Allergan; February 2013.
45 FML Forte [package insert]. Irvine, CA; Allergan; February 2013.
46 FML S.O.P. [package insert]. Irvine, CA; Allergan; February 2005.
47 Flarex [package insert]. Fort Worth, TX; Alcon; December 2006.
48 Lotemax suspension [package insert]. Tampa, FL; Bausch & Lomb; August 2013.
49 Econopred Plus [package insert]. Fort Worth, TX; Alcon; August 2002.


96 Acular [package insert]. Irvine, CA; Allergan; June 2012.

97 Acuvail [package insert]. Irvine, CA; Allergan; June 2016.


99 Nevanac [package insert]. Fort Worth, TX; Alcon; September 2007.


102 Bromday [package insert]. Tampa, FL; Bausch & Lomb; October 2012.

103 Voltaren [package insert]. Duluth, GA; Novartis; March 2008.

104 Maxide [package insert]. Fort Worth, TX; Alcon; December 2015.


106 Durezol [package insert]. Fort Worth, TX; Alcon; July 2016.


108 FML [package insert]. Irvine, CA; Allergan; February 2013.

109 FML Forte [package insert]. Irvine, CA; Allergan; September 2013.


111 Flarex [package insert]. Fort Worth, TX; Alcon; December 2006.
112 Lotemax suspension [package insert]. Tampa, FL; Bausch & Lomb; August 2013.
113 Econopred Plus [package insert]. Fort Worth, TX; Alcon; August 2002.
114 Omnipred [package insert]. Fort Worth, TX; Alcon; October 2007.
115 Pred Forte [package insert]. Irvine, CA; Allergan; August 2013.
116 Pred Mild [package insert]. Irvine, CA; Allergan; April 2014.
118 Vexol [package insert]. Fort Worth, TX; Alcon; February 2012.
119 Triesence [package insert]. Fort Worth, TX; Alcon; November 2007.
120 Voltaren [package insert]. Duluth, GA; Novartis; July 2009.
121 Ocufen [package insert]. Irvine, CA; Allergan; May 2004.
123 Nevanac [package insert]. Fort Worth, TX; Alcon; July 2011.
124 Ozurdex [package insert]. Irvine, CA; Allergan; September 2012.
125 Acuvail [package insert]. Irvine, CA; Allergan; December 2014.
126 Iluvien [package insert]. Fort Worth, TX; Alcon; February 2014.
129 BromSite [package insert]. Cranbury, NJ; Sun; April 2016.
132 Maxidex [package insert]. Fort Worth, TX; Alcon; December 2015.
134 Durezol [package insert]. Fort Worth TX; Alcon; July 2016.
136 FML [package insert]. Irvine, CA; Allergan; February 2013.
137 FML Forte [package insert]. Irvine, CA; Allergan; February 2013.
139 Flarex [package insert]. Fort Worth, TX; Alcon; December 2006.
140 Lotemax suspension [package insert]. Tampa, FL; Bausch & Lomb; August 2013.
141 Econopred Plus [package insert]. Fort Worth, TX; Alcon; August 2002.
142 Omnipred [package insert]. Fort Worth, TX; Alcon; October 2007.
143 Pred Forte [package insert]. Irvine, CA; Allergan; March 2014.
145 Pred Forte [package insert]. Irvine, CA; Allergan; August 2013.
146 Vexol [package insert]. Fort Worth, TX; Alcon; February 2012.
147 Vexol [package insert]. Fort Worth, TX; Alcon; February 2012.
148 Triesence [package insert]. Fort Worth, TX; Alcon; November 2007.
150 Ocufen [package insert]. Irvine, CA; Allergan; July 2012.
152 Nevanac [package insert]. Fort Worth, TX; Alcon; July 2011.
153 Acuvail [package insert]. Irvine, CA; Allergan; December 2014.
154 Iluvien [package insert]. Fort Worth, TX; Alcon; February 2014.
155 Iluvien [package insert]. Alpharetta, GA; Alimera; December 2014.
158 BromSite [package insert]. Cranbury, NJ; Sun; April 2016.
159 Maxidex [package insert]. Fort Worth, TX; Alcon; December 2015.
161 Durezol [package insert]. Fort Worth TX; Alcon; July 2016.
162 FML [package insert]. Irvine, CA; Allergan; February 2013.
163 FML Forte [package insert]. Irvine, CA; Allergan; February 2013.
164 FML S.O.P. [package insert]. Irvine, CA; Allergan; February 2005.
165 Flarex [package insert]. Fort Worth, TX; Alcon; December 2006.
166 Lotemax gel [package insert]. Tampa, FL; Bausch & Lomb; September 2012.
167 Lotemax suspension [package insert]. Tampa, FL; Bausch & Lomb; August 2013.
168 Lotemax suspension [package insert]. Tampa, FL; Bausch & Lomb; August 2013.
169 Omnipred [package insert]. Fort Worth, TX; Alcon; October 2007.
170 Pred Forte [package insert]. Irvine, CA; Allergan; August 2013.
171 Pred Mild [package insert]. Irvine, CA; Allergan; April 2014.
173 Vexol [package insert]. Fort Worth, TX; Alcon; February 2012.
174 Ozurdex [package insert]. Irvine, CA; Allergan; September 2014.
175 Iluvien [package insert]. Alpharetta, GA; Alimera; December 2014.


Nevanac [package insert]. Fort Worth, TX; Alcon; July 2011.


95 Prolensa [package insert]. Tampa, FL; Bausch & Lomb; June 2016.
96 BromSite [package insert]. Cranbury, NJ; Sun; April 2016.
97 Nevanac [package insert]. Fort Worth, TX; Alcon; September 2007.

201 Maxidex [package insert]. Fort Worth, TX; Alcon; December 2015.
203 Durezol [package insert]. Fort Worth TX; Alcon; July 2016.
204 Retisert [package insert]. Rochester, NY; Bausch & Lomb; May 2012.
205 FML [package insert]. Irvine, CA; Allergan; February 2013.
206 FML Forte [package insert]. Irvine, CA; Allergan; February 2013.
207 FML S.O.P. [package insert]. Irvine, CA; Allergan; February 2005.
208 Flarex [package insert]. Fort Worth, TX; Alcon; December 2006.
209 Lotemax suspension [package insert]. Tampa, FL; Bausch & Lomb; August 2013.
210 Econopred Plus [package insert]. Fort Worth TX; Alcon; August 2002.
211 Omnipred [package insert]. Fort Worth, TX; Alcon; October 2007.
212 Pred Forte [package insert]. Irvine Ca; Allergan; August 2013.
213 Pred Mild [package insert]. Irvine Ca; Allergan; April 2014.
215 Vexol [package insert]. Fort Worth, TX; Alcon; February 2012.
216 Triesence [package insert]. Fort Worth, TX; Alcon; November 2007.
218 Ocuflon [package insert]. Irvine, CA; Allergan; May 2004.
220 Nevanac [package insert]. Fort Worth, TX; Alcon; July 2011.
221 Ozurdex [package insert]. Irvine, CA; Allergan; September 2012.
222 Acuvail [package insert]. Irvine, CA; Allergan; December 2014.
223 Ileuro [package insert]. Fort Worth, TX; Alcon; February 2014.
224 Prolensa [package insert]. Tampa, FL; Bausch & Lomb; June 2016.
225 Iluvien [package insert]. Alpharetta, GA; Alimera; December 2014.
227 BromSite [package insert]. Cranbury, NJ; Sun; April 2016.
230 Bromday [package insert]. Tampa, FL; Bausch & Lomb; October 2012.
231 Ocuflon [package insert]. Irvine, CA; Allergan; February 2003.
236 Nevanac [package insert]. Fort Worth, TX; Alcon; September 2007.
237 Acular [package insert]. Irvine, CA; Allergan; June 2012.
238 Acular LS [package insert]. Irvine, CA; Allergan; June 2016.
239 Maxidex [package insert]. Fort Worth, TX; Alcon; December 2015.
etorolac tromethamine 0.5% and prednisolone acetate 1% after inflammation after


Flach AJ, Dolan BJ. Incidence of postoperative posterior opacification following treatment with diclofenac 0.1% and ketorolac 0.5% ophthalmic solutions: 3-year randomized, double-masked, prospective clinical investigation. Trans Am Ophthalmol Soc. 2000; 98:101-105.


